Clipos™ CD27-TF tag mRNA Lipid Nanoparticles

Catalog:CDL23-071-L

Unit Size:200 μL

INQUIRY Datasheet

Specifications
Description CD27 is encoded by the CD27 gene and is a member of the tumor necrosis factor receptor superfamily. This receptor is required for the generation and long-term maintenance of T cell immunity. Through binding to the ligand CD70, CD27 plays a key role in regulating B cell activation and immunoglobulin synthesis and transduces signals leading to the activation of NF-κB and MAPK8/JNK. Under physiological conditions, the expression of CD70 and CD27 is tightly controlled in costimulatory immune responses. CD70 and CD27 are aberrantly expressed in many hematological and solid malignancies, promoting malignant stemness, proliferation and survival. Dysregulation of the CD70-CD27 axis within the tumor and its microenvironment is associated with tumor progression and immunosuppression. Varlilumab, an agonist IgG1 antibody against CD27, stimulates CD27 signaling and appears to stimulate T cells and increase production of cytokines such as IFNγ. As a drug, Varlilumab is in early clinical trials for certain cancers. This product is designed as a tool for the delivery and expression of human TF tagged CD27 mRNA for research. The product leverages the lipid nanoparticle (LNP) technology platform for simple and efficient delivery of CD27-TF mRNA to a variety of mammalian cells in vitro and in vivo. The LNPs used are formulated with SM-102, DSPC, cholesterol and DMG-PEG2000 at an optimal molar concentration for a high rate of encapsulation and efficient mRNA delivery. The CD27-TF fusion protein is approximately 34 kD, consisting of CD27 (291 amino acids) and a C-terminal TF tag (15 amino acids)
Lipid composition SM-102/DSPC/Cholesterol/DMG-PEG2000
Encoding mRNA CD27
In Vitro QC (Cell Types) HEK293S
Technology Applications Protein research
Storage Store at 4°C
Technical Notes Work with mRNA-LNP on ice. It is important to minimize the time that the product spends at room temperature; after handling product during experiments, return immediately to ice.Upon receiving product, briefly pulse spin before opening to ensure product is at bottom of container; it is important not to spin for too long as this may rupture mRNA-LNP’s. Do not vortex. mRNA-LNP products should only be handled with certified RNAase-free reagents and consumables; use of filtered pipette tips is highly recommended
Related Products
Product Name Catalog Lipid composition Liposome Size Price
Clipos™ EGFP mRNA Lipid Nanoparticles CDPM01 SM-102/DSPC/cholesterol/DMG-PEG2000 INQUIRY
Clipos™ mCherry mRNA Lipid Nanoparticles CDPM02 INQUIRY
Clipos™ mCherry-Luciferase mRNA Lipid Nanoparticles CDPM03 INQUIRY
Clipos™ Luciferase mRNA Lipid Nanoparticles CDPM04 SM-102/DSPC/cholesterol/DMG-PEG2000 INQUIRY
Clipos™ CAS 9-RNA Lipid Nanoparticles-HA CDPM05 INQUIRY
Clipos™ ANTI-BCMA mRNA Lipid Nanoparticles CDPM06 SM-102/DSPC/cholesterol/DMG-PEG2000 INQUIRY
Clipos™ ANTI-CD19 mRNA Lipid Nanoparticles CDPM07 SM-102/DSPC/cholesterol/DMG-PEG2000 INQUIRY
Clipos™ ANTI-HER2 mRNA Lipid Nanoparticles CDPM08 SM-102/DSPC/cholesterol/DMG-PEG2000 INQUIRY
Products
Fill out the form below
to receive a quote

GET A QUOTE

Services

Drug Targeting Strategy

Drug Delivery Nanoparticles Formulation

Bioparticles Analysis and Characterization

Bioactive Particles & Fillers Production

Functional Biomedical Coatings

Lipid Library Development for Drug Delivery

Aptamer Targeted Drug Delivery System

Other Types of Drug Delivery

Products

Liposome System

Chelating Agents

Bioactive Matrixes

Porous Organic Materials

Biopolymers & Synthetic Polymers

PROTAC

Transfection

Exosome Products

Cleavable Linkers

Pharmaceutical Excipients (drug/medical grade)

Tissue Engineering Scaffold

  • (USA)
  • (Europe)
Cookie Policy | Privacy Policy | Copyright © 2024 CD Bioparticles. All rights reserved.
0
Inquiry Basket
Inquiry